Hantz Financial Services Inc. Buys New Stake in Stryker Co. (NYSE:SYK)

Hantz Financial Services Inc. bought a new stake in Stryker Co. (NYSE:SYK) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 15,747 shares of the medical technology company’s stock, valued at approximately $5,358,000.

Several other institutional investors have also modified their holdings of the business. Headlands Technologies LLC purchased a new stake in shares of Stryker during the 4th quarter worth $58,000. Precision Wealth Strategies LLC lifted its position in Stryker by 2.1% in the fourth quarter. Precision Wealth Strategies LLC now owns 3,114 shares of the medical technology company’s stock valued at $933,000 after acquiring an additional 65 shares during the last quarter. Mission Wealth Management LP raised its holdings in shares of Stryker by 12.4% in the fourth quarter. Mission Wealth Management LP now owns 2,078 shares of the medical technology company’s stock valued at $622,000 after buying an additional 229 shares during the last quarter. Brighton Jones LLC raised its holdings in shares of Stryker by 1.3% in the fourth quarter. Brighton Jones LLC now owns 3,722 shares of the medical technology company’s stock valued at $1,114,000 after buying an additional 46 shares during the last quarter. Finally, Savant Capital LLC raised its holdings in shares of Stryker by 1.3% in the fourth quarter. Savant Capital LLC now owns 6,552 shares of the medical technology company’s stock valued at $1,962,000 after buying an additional 87 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.7 %

Shares of SYK opened at $360.42 on Friday. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. The firm’s 50-day moving average is $337.13 and its two-hundred day moving average is $341.56. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The firm has a market capitalization of $137.35 billion, a P/E ratio of 41.14, a PEG ratio of 2.78 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company had revenue of $5.42 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same period in the prior year, the business posted $2.54 earnings per share. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, research analysts predict that Stryker Co. will post 12 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Monday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. Evercore ISI reduced their target price on shares of Stryker from $370.00 to $365.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Stifel Nicolaus reduced their target price on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. UBS Group upped their target price on shares of Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Needham & Company LLC upped their target price on shares of Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $373.84.

Insider Buying and Selling at Stryker

In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the sale, the chief financial officer now owns 2,852 shares of the company’s stock, valued at $949,716. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Ronda E. Stryker sold 190,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the transaction, the director now owns 3,316,608 shares of the company’s stock, valued at $1,072,790,023.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares in the company, valued at approximately $949,716. The disclosure for this sale can be found here. Insiders have sold 210,600 shares of company stock valued at $68,330,400 over the last quarter. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.